The 7 major metastatic HER2-positive breast cancer markets are expected to exhibit a CAGR of 1.18% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2023
|
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Growth Rate 2024-2034 | 1.18% |
The metastatic HER2-positive breast cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer is an advanced stage of breast cancer characterized by the presence of HER2 protein overexpression. It tends to be more aggressive than other forms of cancer due to its accelerated growth and increased likelihood of spreading beyond the breast tissue. The symptoms of this illness may include a palpable lump in the breast or underarm, alterations in breast shape or size, skin dimpling, nipple changes, persistent pain, and bone fractures. As the cancer advances, it can spread to distant organs, such as the brain, bones, lungs, or liver, causing further complications. The diagnosis of metastatic HER2-positive breast cancer typically requires a combination of clinical findings and physical investigations. The healthcare provider will also perform numerous diagnostic procedures, including a mammogram or ultrasound, a biopsy of the tumor tissue to confirm HER2 positivity, and imaging studies to determine the extent of metastasis.
The increasing incidences of genetic variations in the BRCA1 and BRCA2 genes, resulting in uncontrolled growth and division of abnormal cells that originate in the breast tissue, are primarily driving the metastatic HER2-positive breast cancer market. In addition to this, the inflating utilization of innovative approaches, such as antibody-drug conjugates and immune checkpoint inhibitors, which help in harnessing the body's immune response to combat cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, including immunotherapies, bisphosphonates, and pain management strategies, aimed at enhancing patients' overall well-being and mitigating treatment-related complications, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, since they involve tailoring treatments based on the genetic makeup of the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive procedures, such as radiofrequency ablation and cryoablation to precisely target and eliminate tumor masses in individuals suffering from the illness is also augmenting the market growth. Furthermore, the escalating application of gene-targeting treatments that aim to correct or inhibit the overexpression of the HER2 gene is expected to drive the metastatic HER2-positive breast cancer market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the metastatic HER2-positive breast cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic HER2-positive breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic HER2-positive breast cancer market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current metastatic HER2-positive breast cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Perjeta (Pertuzumab) | Genentech |
Tukysa (Tucatinib) | Seagen |
Nerlynx (Neratinib) | Puma Biotechnology |
Margenzatm (Margetuximab-Cmkb) | MacroGenics |
Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) | Daiichi Sankyo |
Pertuzumab | Genentech |
Inavolisib | Roche Pharma |
Giredestrant | Roche Pharma |
ZN-A-1041 | Suzhou Zanrong Pharma |
Palbociclib | Pfizer |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Metastatic HER2-Positive Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies